#USA #Houston #Autoimmune Diseases #Autoimmunity BioSolutions #Immuno-Corrective Therapy

Autoimmunity BioSolutions Secures Additional $1 Million to Enhance Therapy Development

Overview

Autoimmunity BioSolutions (ABS), a biotech firm known for its innovative approach to autoimmune therapies, has announced the completion of a $1 million seed funding extension. This new capital injection raises total funds to approximately $3.1 million, positioning the company to reach critical clinical milestones and further develop its unique immuno-corrective therapy aimed at normalizing high levels of soluble IL7 receptor (sIL7R).

Lead investor Eos BioInnovation heads this funding round, supported by a select group of family offices, reflecting their firm belief in ABS's distinct scientific approach. Among the notable new contributors is NewTech Investment Holdings, adding significant value to the financial backing.

Commitment to Change Lives

Eugene Williams, CEO of ABS, expressed gratitude for the ongoing support from investors. He emphasized that the faith displayed by seasoned investors will allow ABS to accelerate much-needed animal model research and patient bio-sample analyses, particularly focusing on Rheumatoid Arthritis (RA).

Targeting a Common Genetic Variant

ABS is pioneering a personalized approach in tackling autoimmune diseases, with a scientific focus on a prevalent single nucleotide polymorphism (SNP) that affects half of the general population. This genetic variant can lead to a 2-3 times increased concentration of sIL7R, which has been linked to worsened disease severity and a lower response to traditional treatments across several autoimmune conditions, such as lupus nephritis and type 1 diabetes.

A Revolutionary Path in Therapy

The company’s goal is to develop a treatment that corrects the elevated sIL7R levels, which contributes to treatment resistance in many autoimmune patients. Unlike standard care that relies on immunosuppressive methods, ABS's therapy offers a targeted approach based on genetic insights. By doing so, it aims to enhance the efficacy of existing treatments for patients struggling with high sIL7R levels.

The Future of Autoimmune Treatments

Autoimmunity BioSolutions is not merely aiming to become another name in the ever-growing field of biotech; it seeks to set new standards for customized therapies that consider genetic makeup. As countless patients continue to seek effective treatments for chronic autoimmune disorders, ABS stands firm in its mission to provide hope through innovative therapies backed by solid science.

About Autoimmunity BioSolutions (ABS)

Founded with a vision to deliver tailor-made therapeutics, ABS is advancing its research to reignite the potential for improved patient outcomes in autoimmune diseases. For continuous updates on their progress and insights into their pioneering research, interested parties can visit their official website or follow their professional updates on LinkedIn.